Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24034051 | 0.83 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL2015627 | 0.80 | MGAM (0.37) | DGAT1GAA | |
| SCHEMBL17486950 | 0.77 | DGAT1 (0.43) | DGAT1HDAC1HDAC2HDAC6 | |
| SCHEMBL26316122 | 0.77 | CYP4F2 (0.50) | GAA | |
| SCHEMBL6686581 | 0.76 | — | — | |
| SCHEMBL31364246 | 0.73 | HDAC6 (0.35) | DGAT1GAAAPLNRHDAC1HDAC2 | |
| SCHEMBL28694851 | 0.72 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL25855692 | 0.72 | DGAT1 (0.39) | DGAT1GAA | |
| SCHEMBL12332053 | 0.72 | DGAT1 (0.46) | DGAT1GAA | |
| SCHEMBL10295968 | 0.71 | DGAT1 (0.41) | DGAT1GAAHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149941-B1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116261561-A | Certain chemical compositions and methods of use thereof | 奧基生物技术有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4149941-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | Algen Biotechnologies, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220289725-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2022-09-15 | — | — | US | disclosed |
| WO-2021231892-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289725-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | CDK9, CDK19, CDK6 | DGAT1 2229/4885GAA 967/4885APLNR 3607/4885 |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | DGAT1 2229/4885GAA 967/4885APLNR 3607/4885 |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | CDK9, CDK19, CDK6 | DGAT1 2229/4885GAA 967/4885APLNR 3607/4885 |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | DGAT1 2229/4885GAA 967/4885APLNR 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.